ARTICLE | Clinical News
Sacituzumab govitecan: Additional Phase I/II data
May 2, 2016 7:00 AM UTC
Interim data from 19 patients with relapsed or refractory metastatic urothelial cancer in the Phase II portion of an open-label, U.S. Phase I/II trial showed that 8, 10 and 12 mg/kg sacituzumab govite...